The abstract is read at the publisher; the summary is JClub's.
Low pretreatment inflammation-nutrition prognostic score (INPS < 0.058) is linked to higher objective response rate and pathological complete response in 312 locally advanced rectal cancer patients.
- Why it matters: Response to immune checkpoint inhibitors in locally advanced rectal cancer is variable, and existing markers like MSI-H/dMMR and PD-L1 CPS may not fully capture who benefits.
- What they did: In a retrospective cohort of 312 LARC patients receiving neoadjuvant chemoradiotherapy with or without PD-1/PD-L1 blockade, INPS was computed as NLR/PNI and tested against ORR, pCR, and PFS using ROC, logistic regression, and Cox analyses.
- The result: Low INPS showed higher ORR (61.3% vs. 29.4%, P < 0.001) and pCR (38.7% vs. 11.8%, P < 0.001), with OR = 3.31 (95% CI: 1.95-5.60, P < 0.001) and AUC 0.765 for ORR, suggesting incremental discrimination beyond MSI-H/dMMR and PD-L1 CPS.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.